Riociguat for the Treatment of Pulmonary Arterial Hypertension

Ghofrani, Hossein-Ardeschir, Galiè, Nazzareno, Grimminger, Friedrich, Grünig, Ekkehard, Humbert, Marc, Jing, Zhi-Cheng, Keogh, Anne M., Langleben, David, Kilama, Michael Ochan, Fritsch, Arno, Neuser, Dieter, Rubin, Lewis J.·2013·New England Journal of Medicine
DOI 10.1056/nejmoa1209655

Cited by (1,000)

Items 201–300 of 1,000

  1. The emerging role of epigenetics in pulmonary hypertension
    Elisabetta Gamen, Werner Seeger, Soni Savai Pullamsetti · 2016 · European Respiratory Journal
  2. Racial and ethnic differences in pulmonary arterial hypertension
    Nadine Al‐Naamani, Jessica K. Paulus, Kari E. Roberts, Michael W. Pauciulo, Katie A. Lutz, William C. Nichols, Steven M. Kawut · 2017 · Pulmonary Circulation
  3. Pulmonary Hypertension and Cardiac Anesthesia: Anesthesiologist's Perspective
    Manjula Sudeep Sarkar, Pushkar Mahendra Desai · 2018 · Annals of Cardiac Anaesthesia
  4. Pharmacotherapy for pulmonary arterial hypertension
    Vishal Yogin Parikh, Anju Bhardwaj, Ajith P. Nair · 2019 · Journal of Thoracic Disease
  5. Current Clinical Management of Pulmonary Arterial Hypertension
    Roham T. Zamanian, Kristina T. Kudelko, Yon K. Sung, Vinicio de Jesús Pérez, Juliana Liu, Edda F. Spiekerkoetter · 2014 · Circulation Research
  6. Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis
    Benjamin Daniel Fox, Osnat Shtraichman, David Langleben, Avi Shimony, Mordechai Reuven Kramer · 2016 · Canadian Journal of Cardiology
  7. Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH): Recent and advanced data
    Benjamin Thoreau, Luc Mouthon · 2023 · Autoimmunity Reviews
  8. Riociguat for Pulmonary Hypertension — A Glass Half Full
    Stephen L. Archer · 2013 · New England Journal of Medicine
  9. The 6MWT as a prognostic tool in pulmonary arterial hypertension: results from the COMPERA registry
    Thomas A. Zelniker, Dörte Huscher, Anton Vonk Noordegraaf, Ralf Ewert, Tobias J. Lange, Hans F. E. Klose, Daniel Dumitrescu, Michael Halank, M Held, Henning J. Gall et al. · 2018 · Clinical Research in Cardiology
  10. Redox Signaling as a Therapeutic Target to Inhibit Myofibroblast Activation in Degenerative Fibrotic Disease
    Natalie Sampson, Peter Berger, Christoph Zenzmaier · 2014 · BioMed Research International
  11. Treatment of pulmonary arterial hypertension in children
    Heiner Latus, Tammo Delhaas, Dietmar Schranz, Christian Apitz · 2015 · Nature Reviews Cardiology
  12. The role of combination therapy in managing pulmonary arterial hypertension
    Hossein Ardeschir Ghofrani, Marc J.C. Humbert · 2014 · European Respiratory Review
  13. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension
    Huan-long Liu, Xueyan Chen, Jie-Ru Li, Suwen Su, Tao Ding, Chenxia Shi, Yunfa Jiang, Zhong‐ning Zhu · 2016 · CHEST Journal
  14. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial
    Pavel Jansa, Tomás Pulido · 2017 · American Journal of Cardiovascular Drugs
  15. The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats
    Philipp Schwabl, Ksenia Brusilovskaya, Paul Supper, David Josef Maria Bauer, Philipp Königshofer, Florian Riedl, Hubert Hayden, Claudia Daniela Fuchs, Judith Stift, Georg Oberhuber et al. · 2018 · Scientific Reports
  16. Sex Differences in Pulmonary Hypertension
    Juan José Rodríguez-Arias, Ana García‐Álvarez · 2021 · Frontiers in Aging
  17. Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach
    Laurențiu Stoicescu, Dana Crișan, Claudiu Morgovan, Lucreția Avram, Stéliana Ghibu · 2024 · International Journal of Molecular Sciences
  18. Pulmonary hypertension in connective tissue diseases: an update
    Ramya Aithala, Anoop George Alex, Debashish Danda · 2017 · International Journal of Rheumatic Diseases
  19. The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension
    Roberto Badagliacca, Silvia Papa, Hiromi Matsubara, Irene Marthe Lang, Roberto Poscia, Giovanna Manzi, Carmine Dario Vizza · 2019 · International Journal of Cardiology
  20. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Alberto Maria Marra, Benjamin Egenlauf, Nicola Ehlken, Christine Fischer, Christina A. Eichstaedt, Christian Nagel, Eduardo Bossone, Antonio Cittadini, Michael Halank, Henning J. Gall et al. · 2015 · International Journal of Cardiology
  21. New Pharmacological Strategies to Increase cGMP
    Alessia Buglioni, John C. Jr Burnett · 2015 · Annual Review of Medicine
  22. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges
    Annie‐Christine Lajoie, Sébastien Bonnet, Steeve Provencher · 2017 · Pulmonary Circulation
  23. Riociguat for Sarcoidosis-Associated Pulmonary Hypertension
    Robert Phillip Baughman, Oksana A. Shlobin, Rohit Gupta, Peter J. Engel, Jeffrey I. Stewart, Elyse E. Lower, Franck Rahaghi, Joyce Zeigler, Steven D. Nathan · 2021 · CHEST Journal
  24. Improved Survival for Patients with Systemic Sclerosis–associated Pulmonary Arterial Hypertension: The Johns Hopkins Registry
    Hussein J. Hassan, Mario Naranjo, Nour Ayoub, Traci Housten, Steven Hsu, Aparna Balasubramanian, Catherine E. Simpson, Rachel L. Damico, Stephen C. Mathai, Todd M. Kolb et al. · 2022 · American Journal of Respiratory and Critical Care Medicine
  25. Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
    Vincent Sobanski, David Launay, Eric HACHULLA, Marc J.C. Humbert · 2016 · Current Rheumatology Reports
  26. Discovery of Novel Pyrazolo[3,4- b ] Pyridine Derivatives with Dual Activities of Vascular Remodeling Inhibition and Vasodilation for the Treatment of Pulmonary Arterial Hypertension
    Liqing Hu, Lijun Li, Qi Chang, Songsen Fu, Jia Qin, Zhuo Chen, Xiaohui Li, Qinglian Liu, Gaoyun Hu, Qianbin Li · 2020 · Journal of Medicinal Chemistry
  27. Management of Raynaud Phenomenon and Digital Ulcers in Scleroderma
    Laura C. Cappelli, Fredrick M. Wigley · 2015 · Rheumatic Disease Clinics of North America
  28. Ambrisentan: a review of its use in pulmonary arterial hypertension
    Belinda N. Rivera‐Lebron, Michael G. Risbano · 2017 · Therapeutic Advances in Respiratory Disease
  29. Nitric oxide and pulmonary arterial hypertension
    Adrian H. Chester, Magdi Habib Yacoub, Salvador Moncada · 2017 · Global Cardiology Science and Practice
  30. Systemic Sclerosis-Associated Pulmonary Hypertension: Spectrum and Impact
    Mario Naranjo, Paul M. Hassoun · 2021 · Diagnostics
  31. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options
    Jean‐Sébastien Hulot, Jean‐Noël Trochu, Erwan Donal, Michel Galinier, Damien Logeart, Pascal de Groote, Yves Juillière · 2021 · Expert Opinion on Pharmacotherapy
  32. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)
    Justin A. Ezekowitz, Yinggan Zheng, Alain Cohen Solal, Vojtěch Melenovský, Jorge Escobedo, Javed Butler, Adrian F. Hernandez, Carolyn S.P. Lam, Christopher M. O’Connor, Burkert Mathias Pieske et al. · 2021 · Circulation
  33. Vascular Effects of Endothelin Receptor Antagonists Depends on Their Selectivity for ETA Versus ETB Receptors and on the Functionality of Endothelial ETB Receptors
    Marc Iglarz, Pauline Steiner, Daniel Wanner, Markus Rey, Patrick Hess, Martine Clozel · 2015 · Journal of Cardiovascular Pharmacology
  34. Oxidative and nitrosative signalling in pulmonary arterial hypertension — Implications for development of novel therapies
    Thomas Hansen, Keyvan Karimi Galougahi, David Stephen Celermajer, Nathalie B. Rasko, Owen Tang, Kristen J. Bubb, Gemma A. Figtree · 2016 · Pharmacology & Therapeutics
  35. Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study
    Felix Gerhardt, Daniel Dumitrescu, Carina Gärtner, Ralf Beccard, Thomas Viethen, Tilmann Kramer, Stephan Ernst Baldus, Martin Hellmich, Eckhard Schönaü, Stephan Rosenkranz · 2017 · Heart
  36. Genetic alterations in the NO-cGMP pathway and cardiovascular risk.
    J. Wobst, H. Schunkert, T. Kessler · 2018 · Nitric oxide
  37. Soluble Guanylate Cyclase as a Novel Treatment Target for Osteoporosis
    Jisha Joshua, Gerburg K. Schwaerzer, Hema Kalyanaraman, Esther Cory, Robert L. Sah, Mofei Li, Florin Vaida, Gerry R. Boss, Renate B. Pilz · 2014 · Endocrinology
  38. Effect of Pulmonary Arterial Hypertension-Specific Therapies on Health-Related Quality of Life
    Gilles Rival, Yves Lacasse, Sylvie Martin, Sébastien Bonnet, Steeve Provencher · 2014 · CHEST Journal
  39. Lewis Acid‐Mediated [3+3] Annulation for the Construction of Substituted Pyrimidine and Pyridine Derivatives
    Yao Zhou, Zhonghe Tang, Qiuling Song · 2017 · Advanced Synthesis & Catalysis
  40. Regulation of Pulmonary Vascular Smooth Muscle Contractility in Pulmonary Arterial Hypertension: Implications for Therapy
    Melissa A. Lyle, Jonathan P. Davis, Frank V. Brozovich · 2017 · Frontiers in Physiology
  41. Clinical Trials Update
    Fernando Torres · 2013 · Advances in Pulmonary Hypertension
  42. Role of the nitric oxide–soluble guanylyl cyclase pathway in obstructive airway diseases
    Lisa L. Dupont, Constantinos Glynos, Ken R. Bracke, Peter Brouckaert, Guy Brusselle · 2014 · Pulmonary Pharmacology & Therapeutics
  43. Early intervention in the management of pulmonary arterial hypertension: clinical and economic outcomes
    Charles D. Burger, Mohamedanwar Ghandour, Divya Padmanabhan Menon, Haytham Helmi, Raymond L. Benza · 2017 · ClinicoEconomics and Outcomes Research
  44. Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding
    Nabham Rai, Swathi Veeroju, Yves Schymura, Wiebke Janssen, Astrid Wietelmann, Baktybek K. Kojonazarov, Norbert Weißmann, Johannes‐Peter Stasch, Hossein Ardeschir Ghofrani, Werner Seeger et al. · 2018 · BioMed Research International
  45. Treatment Barriers in Portopulmonary Hypertension
    Batool Jamal AbuHalimeh, Michael J. Krowka, Adriano R. Tonelli · 2018 · Hepatology
  46. Elevation of Plasma Cell-Free Hemoglobin in Pulmonary Arterial Hypertension
    Evan L. Brittain, David R. Janz, Eric D. Austin, Julie A. Bastarache, Lisa A Wheeler, Lorraine B. Ware, Anna Ryan Hemnes · 2014 · CHEST Journal
  47. From comorbidities to heart failure with preserved ejection fraction: a story of oxidative stress
    Constantijn Franssen, H. Sophia Chen, Nazha Hamdani, Walter J. Paulus · 2015 · Heart
  48. Connective tissue disease-related pulmonary arterial hypertension
    Vivek Thakkar, Edmund Lau · 2016 · Best Practice & Research Clinical Rheumatology
  49. Comparative Effectiveness of Pharmacologic Interventions for Pulmonary Arterial Hypertension
    Snigdha Jain, Rohan Khera, Saket R. Girotra, David B. Badesch, Zhen Wang, Mohammad Hassan Murad, Amy Blevins, Gregory A. Schmidt, Siddharth Singh, Alicia K. Gerke · 2016 · CHEST Journal
  50. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
    Tian‐Yu Lian, Xin Jiang, Zhi‐Cheng Jing · 2017 · Drug Design Development and Therapy
  51. Riociguat Reduces Infarct Size and Post-Infarct Heart Failure in Mouse Hearts: Insights from MRI/PET Imaging
    Carmen Methner, Guido Buonincontri, Chou-Hui Hu, Ana Vujić, Axel Kretschmer, Stephen J. Sawiak, Adrian Carpenter, Johannes‐Peter Stasch, Thomas Krieg · 2013 · PLoS ONE
  52. Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR Trial
    Yogesh N.V. Reddy, Javed Butler, Kevin Joseph Anstrom, Robert O. Blaustein, Marc P. Bonaca, Stefano Corda, Justin Adrian Ezekowitz, Carolyn S.P. Lam, Eldrin Foster Lewis, JoAnn Lindenfeld et al. · 2024 · European Journal of Heart Failure
  53. Pulmonary Complications of Portal Hypertension
    Rodrigo Cartin‐Ceba, Michael J. Krowka · 2019 · Clinics in Liver Disease
  54. Acute Effects of Riociguat in Borderline or Manifest Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
    Hossein Ardeschir Ghofrani, Gerd Staehler, Ekkehard Grünig, Michael Halank, Veselin L. Mitrović, Sigrun Unger, Wolfgang Mueck, Reiner Frey, Friedrich Grimminger, RALPH THEO SCHERMULY et al. · 2015 · Pulmonary Circulation
  55. New horizons in pulmonary arterial hypertension therapies
    Nazzareno Galiè, Hossein Ardeschir Ghofrani · 2013 · European Respiratory Review
  56. Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study
    Kathryn Coyle, Doug Coyle, Julie Blouin, Karen S. Lee, Mohammed F. Jabr, Khai Trieu Tran, Lisa Marie Mielniczuk, John R. Swiston, Mike Innes · 2016 · PharmacoEconomics
  57. REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat
    Raymond L. Benza, Harrison W. Farber, Adaani Frost, Ekkehard Grünig, Marius M. Hoeper, Dennis Busse, Christian Meier, Sylvia M. Nikkho, Hossein Ardeschir Ghofrani · 2018 · The Journal of Heart and Lung Transplantation
  58. Raynaud’s phenomenon: Current concepts
    Thomas P. Stringer, Alisa N. Femia · 2018 · Clinics in Dermatology
  59. Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis
    Saja Almaaitah, Kristin B. Highland, Adriano R. Tonelli · 2020 · Integrated Blood Pressure Control
  60. The Nitric Oxide Pathway in Pulmonary Arterial Hypertension: Pathomechanism, Biomarkers and Drug Targets
    Zsófia Lázár, Martina Mészáros, András Bikov · 2020 · Current Medicinal Chemistry
  61. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension
    Cheng Chu Zeng, Jing Liu, Xialei Zheng, Xinqun Hu, Yuhu He · 2023 · Respiratory Research
  62. New insights into the role of soluble guanylate cyclase in blood pressure regulation
    Emmanuel S. Buys, Patrick Yves Sips · 2014 · Current Opinion in Nephrology & Hypertension
  63. A “green” diet-based approach to cardiovascular health? Is inorganic nitrate the answer?
    Rathod, Krishnaraj Sinhji, Velmurugan, Shanti, Ahluwalia, Amrita · 2016 · Molecular Nutrition & Food Research
  64. Current management strategies for systemic sclerosis.
    Svetlana I. Nihtyanova, Voon Hong Ong, Christopher Paul Denton · 2014 · PubMed
  65. Interfacial Residues Promote an Optimal Alignment of the Catalytic Center in Human Soluble Guanylate Cyclase: Heterodimerization Is Required but Not Sufficient for Activity
    Franziska Seeger, Royston S. Quintyn, Akiko Tanimoto, Gareth J. Williams, John A. Tainer, Vicki Hopper Wysocki, Elsa D. Garcin · 2014 · Biochemistry
  66. FRET-based cyclic GMP biosensors measure low cGMP concentrations in cardiomyocytes and neurons
    Gaia Calamera, Dan Li, Andrea Hembre Ulsund, Jeong Joo Kim, Oliver C. Neely, Lise Román Moltzau, Marianne Bjørnerem, David J. Paterson, Choel Kim, Finn Olav Levy et al. · 2019 · Communications Biology
  67. Newer approaches and novel drugs for inhalational therapy for pulmonary arterial hypertension
    Ali Asghar Keshavarz, Hossam Kadry, Ahmed Alobaida, Fakhrul Ahsan · 2020 · Expert Opinion on Drug Delivery
  68. The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension
    Rubina M. Khair, Chisom Nwaneri, Rachel L. Damico, Todd M. Kolb, Paul M. Hassoun, Stephen C. Mathai · 2016 · Annals of the American Thoracic Society
  69. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study
    Michael Halank, Marius M. Hoeper, Hossein Ardeschir Ghofrani, F. Joachim Meyer, G. Stähler, Jürgen Behr, Ralf Ewert, Monique Fletcher, Pablo C. Colorado, Sylvia M. Nikkho et al. · 2017 · Respiratory Medicine
  70. Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies
    Alain Lescoat, David Roofeh, Masataka Kuwana, Robert Lafyatis, Yannick Allanore, Dinesh Khanna · 2021 · Clinical Reviews in Allergy & Immunology
  71. Comprehensive review on novel targets and emerging therapeutic modalities for pulmonary arterial Hypertension
    Sagar Dhoble, Vandana Bharat Patravale, Edward Weaver, Dimitrios A. Lamprou, Tanmay Patravale · 2022 · International Journal of Pharmaceutics
  72. Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Diana Khaybullina, Ami K. Patel, Tina Zerilli · 2014 · Europe PMC (PubMed Central)
  73. Pulmonary Vasodilator Therapy in Persistent Pulmonary Hypertension of the Newborn
    Thomas J. Kulik, James Ernest Lock · 1984 · Clinics in Perinatology
  74. Pulmonary hypertension: diagnostic and therapeutic challenges
    Wassim H. Fares, Isabel S. Bazan · 2015 · Therapeutics and Clinical Risk Management
  75. Riociguat: A Novel New Drug for Treatment of Pulmonary Hypertension
    Charles T. Makowski, Richard W. Rissmiller, Wendy Bullington · 2015 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  76. Gender-related differences in pulmonary arterial hypertension targeted drugs administration
    Alberto Maria Marra, Nicola Benjamin, Christina A. Eichstaedt, Andrea Salzano, Michele Arcopinto, Luna Gargani, Michele D’Alto, Paola Argiento, Lorenzo Falsetti, Paolo Di Giosia et al. · 2016 · Pharmacological Research
  77. Role of smooth muscle cell p53 in pulmonary arterial hypertension
    Takayuki Wakasugi, Ippei Shimizu, Yohko Yoshida, Yuka Hayashi, Ryutaro Ikegami, Masayoshi Suda, Goro Katsuumi, Masaaki Nakao, Makoto Hoyano, Takeshi Kashimura et al. · 2019 · PLoS ONE
  78. Targeted Drugs for Treatment of Pulmonary Arterial Hypertension: Past, Present, and Future Perspectives
    Wei Zheng, Zhen Wang, Xiangrui Jiang, Qingjie Zhao, Jingshan Shen · 2020 · Journal of Medicinal Chemistry
  79. Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study
    Steven D. Nathan, Vincent Cottin, Juergen Behr, Marius M. Hoeper, Fernando J. Martínez, Tamera Jo Corte, ANNE M. KEOGH, Hanno H. Leuchte, Nesrin Moğulkoç, Silvia Ulrich et al. · 2021 · The Journal of Heart and Lung Transplantation
  80. 2018 TSOC guideline focused update on diagnosis and treatment of pulmonary arterial hypertension
    Wei‐Chun Huang, Chih‐Hsin Hsu, Shih‐Hsien Sung, Wan‐Jing Ho, Chun‐Yuan Chu, Chih-Ping Chang, Yu‐Wei Chiu, Chun‐Hsien Wu, Wei‐Ting Chang, Lin Lin et al. · 2019 · Journal of the Formosan Medical Association
  81. Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets
    Michael Mähler, Marie Hudson, Chelsea Bentow, Fabrece Roup, Lorenzo Beretta, Carmen Pilar Simeón‐Aznar, Alfredo Guillén del Castillo, Sı́lvia Casas, Marvin J. Fritzler · 2020 · Autoimmunity Reviews
  82. Riociguat: Clinical research and evolving role in therapy
    James R. Klinger, Murali M. Chakinala, David Langleben, Stephan Rosenkranz, Olivier Sitbon · 2020 · British Journal of Clinical Pharmacology
  83. Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment
    Devashis Mukherjee, Girija Ganesh Konduri · 2021 · Comprehensive physiology
  84. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension - web addenda
    Nazzareno Galiè, Marc J.C. Humbert, Jean‐Luc Vachiéry, Simon Gibbs, Irene Marthe Lang, Adam Torbicki, Gérald Simonneau, Andrew J. Peacock, Anton Vonk Noordegraaf, Maurice Beghetti et al. · 2015 · ORBi (University of Liège)
  85. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial
    Carmine Dario Vizza, Pavel Jansa, Simon A. Teal, Theresa Dombi, Duo Zhou · 2017 · BMC Cardiovascular Disorders
  86. Beneficial effects of bile acid receptor agonists in pulmonary disease models
    Paolo Comeglio, Annamaria Morelli, Luciano Adorini, Mario Maggi, Linda Vignozzi · 2017 · Expert Opinion on Investigational Drugs
  87. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases
    Peter Sandner, Eva‐Maria Becker‐Pelster, Johannes Peter Stasch · 2018 · Nitric Oxide
  88. Selexipag for the treatment of pulmonary arterial hypertension
    Nika Skoro‐Sajer, Irene Marthe Lang · 2014 · Expert Opinion on Pharmacotherapy
  89. Palliative care in pulmonary arterial hypertension: an underutilised treatment
    Ghaleb Khirfan, Adriano R. Tonelli, Jennifer L. Ramsey, Sandeep Sahay · 2018 · European Respiratory Review
  90. Riociguat for treatment of pulmonary hypertension in COPD: a translational study
    Alexandra Pichl, Natascha Sommer, Mariola Bednorz, Michael Seimetz, Stefan Hadžić, Stefan Kuhnert, Simone Kraut, Elsa Tadele Roxlau, Baktybek K. Kojonazarov, Jochen Wilhelm et al. · 2019 · European Respiratory Journal
  91. Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction
    Thenappan Thenappan, Kurt W. Prins, Rebecca J. Cogswell, Sanjiv Jayendra Shah · 2015 · Canadian Journal of Cardiology
  92. REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival
    Raymond L. Benza, Harrison W. Farber, Adaani Frost, Hossein Ardeschir Ghofrani, Miguel Ángel Gómez‐Sánchez, David Langleben, Stephan Rosenkranz, Dennis Busse, Christian Meier, Sylvia M. Nikkho et al. · 2017 · The Journal of Heart and Lung Transplantation
  93. Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies
    Stefan Reinders, Eva‐Maria Didden, Rose Chik-ying Ong · 2024 · Respiratory Research
  94. HIV ‐associated pulmonary arterial hypertension: from bedside to the future
    Michele Correale, Giuseppe Antonio Palmiotti, Maria Maddalena Lo Storto, Deodata Montrone, Maria Pia Foschino Barbaro, Matteo Di Biase, Donato Lacedonia · 2015 · European Journal of Clinical Investigation
  95. Hospital and intensive care unit management of decompensated pulmonary hypertension and right ventricular failure
    Angel Coz Yataco, Melina Aguinaga-Meza, Ketan P. Buch, Margaret Disselkamp · 2015 · Heart Failure Reviews
  96. Soluble Guanylate Cyclase Stimulators and Activators: Where are We and Where to Go?
    Si-Jia Xiao, Qianbin Li, Liqing Hu, Zutao Yu, Jie Yang, Qi Chang, Zhuo Chen, Gaoyun Hu · 2019 · Mini-Reviews in Medicinal Chemistry
  97. Advances in the management of pulmonary arterial hypertension
    Himanshu Deshwal, Tatiana Weinstein, Roxana Sulica · 2021 · Journal of Investigative Medicine
  98. Treatment of idiopathic/hereditary pulmonary arterial hypertension
    Hiromi Matsubara, Aiko Ogawa · 2014 · Journal of Cardiology
  99. YC-1 Binding to the β Subunit of Soluble Guanylyl Cyclase Overcomes Allosteric Inhibition by the α Subunit
    Purohit, Rahul, Fritz, Bradley G., The, Juliana, Issaian, Aaron, Weichsel, Andrzej, David, Cynthia L., Campbell, Eric, Hausrath, Andrew C., Rassouli-Taylor, Leida, Garcin, Elsa D. et al. · 2014 · Biochemistry
  100. Exploring hypertension genome‐wide association studies findings and impact on pathophysiology, pathways, and pharmacogenetics
    Claudia Cabrera, Fu Liang Ng, Helen R. Warren, Michael R. Barnes, Patricia B. Munroe, Mark J. Caulfield · 2015 · WIREs Systems Biology and Medicine